Safety and pharmacodynamic efficacy of eculizumab in aneurysmal subarachnoid hemorrhage (CLASH): A phase 2a randomized clinical trial

INTRODUCTION: Complement C5 antibodies reduce brain injury after experimental subarachnoid hemorrhage. PATIENTS AND METHODS: In this randomized, controlled, open-label, phase 2a clinical trial with blinded-outcome assessment, we included adult aneurysmal subarachnoid hemorrhage (aSAH) patients admit...

Descripción completa

Detalles Bibliográficos
Autores principales: Koopman, Inez, Tack, Reinier WP, Wunderink, Herman F, Bruns, Anke HW, van der Schaaf, Irene C, Cianci, Daniela, Gelderman, Kyra A, van de Ridder, Inge M, Hol, Elly M, Rinkel, Gabriel JE, Vergouwen, Mervyn DI
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683736/
https://www.ncbi.nlm.nih.gov/pubmed/37606053
http://dx.doi.org/10.1177/23969873231194123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10683736/
https://www.ncbi.nlm.nih.gov/pubmed/37606053
http://dx.doi.org/10.1177/23969873231194123

Ejemplares similares